| Primary information |
|---|
| ID | 1767 |
| ThPP ID | Th1185 |
| Therapeutic Peptide/Protein Name | Human clostridium tetani toxoid immune globulin |
| Sequence | NA view full sequnce in fasta |
| Functional Classification | IIIb |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting Point (℃) | NA |
| Half Life | NA |
| Description | NA |
| Indication/Disease | It is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain (see below). It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus. |
| Pharmacodynamics | It supplies passive immunity to those individuals who have low or no immunity to the toxin produced by the tetanus organism, Clostridium tetani. The antibodies act to neutralize the free form of the powerful exotoxin produced by this bacterium. |
| Mechanism of Action | NA |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | NA |
| Volume of Distribution | NA |
| Clearance | NA |
| Categories | NA |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Information of corresponding available drug in the market |
|---|
| Brand Name | Hypertet S/d |
| Company | GRIFOLS USA, LLC |
| Brand Discription | HyperTET® S/D treated with solvent/detergent is a colorless to pale yellow or pink sterile solution of tetanus hyperimmune immune globulin for intramuscular administration; it is preservative-free, in a latex-free delivery system. HyperTET S/D is prepared by cold ethanol fractionation fromthe plasma of donors immunized with tetanus toxoid. |
| Prescribed for | HyperTET S/D is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain (see below). It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus. |
| Chemical Name | NA |
| Formulation | 250 [iU]/mL |
| Physcial Appearance | Injection |
| Route of Administration | Intramuscular |
| Recommended Dosage | NA |
| Contraindication | NA |
| Side Effects | Slight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin there have been a few isolated occurrences of angio neurotic edema, nephrotic syndrome, and anaphylactic shock after injection. |
| Useful Link | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=393fa198-7e07-4162-bd0a-9d873f1544a9&type=display |
| PubMed ID | NA |
| 3-D Structure | N.A. |